Smith & Nephew snare wound care biotech Healthpoint for $782M; Ironwood wins European OK for linaclotide;

 @FierceBiotech: In case you missed it yesterday, check out the 10 top drug launch disasters on FiercePharma.com: Special Report | Follow @FierceBiotech

 @JohnCFierce: Sanofi jumps on board Selecta's immunotherapy platform with $900M discovery deal. News | Follow @JohnCFierce

 @RyanMFierce: A Dutch group's study suggests pharma's reliance on CROs to do studies in dev. world could leave patients at risk. More | Follow @RyanMFierce

> Smith & Nephew ($SNN) has struck a deal to buy Healthpoint Biotherapeutics in Texas for $782 million. The deal nets Healthpoint's R&D work on bioactive wound care. Story

> Ironwood ($IRWD) and partner Almirall say that European regulators have approved their irritable bowel syndrome drug linaclotide. It will be sold in Europe as Constella. Story

> Aveo ($AVEO) and Astellas report that the FDA has accepted their application for tivozanib, an experimental new therapy for renal cell carcinoma, for review. The PDUFA date on the regular review is expected to be July 28, 2013. Release

> Novartis ($NVS) boasts that it will highlight more than 140 presentations on key data from its oncology portfolio at the leading year-end scientific meetings. Release

Pharma News

@FiercePharma: Growing price gap between branded drugs, generics = more incentive for payers to push the cheaper copies. More | Follow @FiercePharma

> FTC: Generic-fighting product tweaks violate antitrust laws. Article

> Pharma fights European austerity with product pullbacks. Report

> GSK, J&J earn top marks for boosting access to meds for poor. News

Medical Device News

 @FierceMedDev: If you haven't, check out the top Dx sellers for 2012. Many are already outpacing 2011 annual sales as of Q3. Special Report | Follow @FierceMedDev

@MarkHFierce: Considering how big catheter ablation is becoming, when will a big suitor try to snatch up Endosense? More | Follow @MarkHFierce

 @DamianFierce: In the wake of J&J's $21B deal for Synthes, medical device and diagnostics M&A was a little quieter in 2012. Special Report | Follow @DamianFierce

> Edwards' mitral heart valve wins Chinese SFDA nod. More

> GE exec: Fiscal cliff is stalling medical device sales. Story

> Given Imaging submits PillCam Colon 2 for FDA clearance. News

Biomarkers News

> Finding gene biomarkers could help diagnosis of rare and lethal cancer. Item

> Researchers find genetic marker for newborn respiratory distress. Article

> Biomarker helps brain cancer snack on sugar. Story

> Biomarkers could change the course of Chagas disease treatment. More

> Gene predicts resistance to Pfizer's Xalkori. Report

Drug Delivery News

> Pfizer completes $680M NextWave acquisition. Item

> Clinical results for Intellipharmaceutics' CR pregabalin. News

> CeQur's insulin pump approved for European market. Article

> Applications expand for Rhenovia's transdermal RHEpatch. Story

And Finally… Investigators say that a big belly on a man greatly increases the risk of osteoporosis. Release

 

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.